PBPK/PD modeling is essential in modern drug development. Traditional drug development methods frequently rely on trial and error, which can be time-consuming, costly, and could be risky. Predicting pharmacokinetics (PK) of drugs in pregnant women, encompassing the intricate aspect of placental drug transfer, remains a complex task. This study was to compare of simulated or predicted and observed (previously published approaches) pharmacokinetic parameters among the four antiviral drugs in pregnant and non-pregnant women. In addition, this investigation endeavors to construct and assess physiologically-based pharmacokinetic (PBPK) models specific to maternal-fetal interactions for four antiviral drugs, Acyclovir, Emtricitabine, Dolutegravir (DTG) and Raltegravir (RAL). PBPK models were built with the Open Systems Pharmacology software suite (PK-Sim/MoBi). Different approaches to inform placental drug transfer were applied and compared. Model performance was evaluated using in vivo all 4 a forementioned antiviral maternal plasma concentrations during the 2nd and 3rd trimesters and umbilical vein concentrations at delivery. All clinical in vivo data were obtained from the International Maternal paediatric and Adolescent AIDS Clinical Trials (IMPAACT) Network P1026s study. The PBPK models successfully predicted plasma concentration-time profiles of four antiviral drugs in the 2nd and 3rd trimesters and most predicted PK parameters fell within a 1.33-fold error range. Predicted umbilical vein concentrations of DTG among others were in reasonable agreement with in vivo data but were sensitive to changes in the placental partition coefficient and transplacental clearance. Maternal-fetal PBPK modeling reliably predicted maternal PK of previously mentioned antiviral during pregnancy. For the fetal PK, data on the unbound fraction of highly protein-bound DTG has proven to be important to adequately capture changes in total clearance in silico. More research efforts, along with clinical data, are needed to verify the predictions of fetal PK of antiviral. In conclusion, the findings suggest the feasibility of employing physiologically-based pharmacokinetic (PBPK) models to assess the disposition of antiviral drugs in pregnant women and their fetuses.
Competing Interest StatementThe authors have declared no competing interest.
Clinical Protocolshttps://github.com/Open-Systems-Pharmacology/OSP-PBPK-Model-Library
Funding StatementThis study did not receive any fundin
Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data AvailabilityData Availability from Open Systems Pharmacology provides research data availability through its platforms like PK-Sim and MoBi. These tools enable researchers to build, simulate, and analyze quantitative systems pharmacology models. The availability of these resources promotes data sharing and collaboration, enhancing the reproducibility and transparency of research. By offering access to comprehensive pharmacokinetic and pharmacodynamic modeling data, Open Systems Pharmacology supports the development of new drugs and the advancement of pharmacological research.
留言 (0)